Fundraising Fox

Neutrolis

Cambridge, US · Founded 2017 · Delaware corporation · 1 known investors

neutrolis.com

Founders & leadership

AH
Abdul Hakkim RahamathullahDirector, Executive Officer, Promoter
TF
Toby FoxDirector, Executive Officer, Promoter
GC
Gerald ChanDirector
AA
Anthony AiudiDirector
JS
John SundyDirector

Investors · 1

Competitors · 9

by search overlap
Diabetes Prevention Program11 shared keywords
PatSnap8 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Neurelis5 shared keywords
Thumbnail for Nurix5 shared keywords
Quralis4 shared keywordsQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
Cleveland Clinic, 20224 shared keywordsCleveland Clinic is a patient-centered academic medical center providing clinical care, research, and medical education. The organization offers services ranging from primary care and virtual visits to specialized treatment, clinical trials, and advanced medical research.
ResearchGate4 shared keywords
Exelixis4 shared keywords
Parabilis Medicines3 shared keywordsHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.

Companies competing with Neutrolis for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
$3.5MraisedJul 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John SundyDirector
  • Gerald ChanDirector
  • Anthony AiudiDirector, Executive Officer, Promoter
  • Toby FoxDirector, Executive Officer, Promoter
  • Abdul Hakkim RahamathullahDirector, Executive Officer, Promoter
Offering amount
$10M
Amount sold
$3.5M
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$965KraisedApr 2025 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John SundyDirector
  • Abdul Hakkim RahamathullahDirector, Executive Officer, Promoter
  • Toby FoxDirector, Executive Officer, Promoter
  • Gerald ChanDirector
  • Anthony AiudiDirector
Offering amount
$1M
Amount sold
$965K
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$23.1MraisedDec 2021 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gerald ChanDirector
  • Toby FoxExecutive Officer, Director, Promoter
  • Abdul Hakkim RahamathullahExecutive Officer, Director, Promoter
  • Anthony AiudiDirector
Offering amount
$40.6M
Amount sold
$23.1M
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$251.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$209.5K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.